Results of Operations and Financial Condition. On July 30, 2026, Lite Strategy, Inc. (the "Company") issued a press release announcing the repurchases of 13% of its outstanding shares of common stock since December 2025, increasing the amount of Litecoin owned by the Company per outstanding share of common stock. This press release includes certain financial information regarding the Company as of June 30, 2026. The text of the press release is included as Exhibit 99.1 to this Current Report…

Results of Operations and Financial Condition. On May 13, 2026, Lite Strategy, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2026. The text of the press release is included as an exhibit to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Results of Operations and Financial Condition. On February 17, 2026, Lite Strategy, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended December 31, 2025. The text of the press release is included as an exhibit to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Ex…

The filing is about the approval of an equity compensation plan and related options grant, not a management change.

Chief Executive Officer, Chief Financial Officer, Secretary — Justin J. File: Justin J. File was promoted to Chief Executive Officer in addition to his current roles of Chief Financial Officer and Secretary.

Changes in Registrant’s Certifying Accountant. The Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Lite Strategy, Inc. (the “Company”) undertook a selection process to determine the Company’s independent registered public accounting firm for the current fiscal year ending June 30, 2026. On December 2, 2025, the Committee approved the engagement of CBIZ CPAs P.C. (“CBIZ CPAs”) as its independent registered public accounting firm for the fiscal year ending June 30,…

Mr. File: The filing details a compensatory arrangement involving stock options for Mr. File.

Chief Executive Officer — Justin J. File: Mr. File was promoted to the permanent role of Chief Executive Officer and appointed as a member of the Board.

Director — Thomas C. Reynolds, M.D., Ph.D.: Dr. Reynolds resigned as a director of the Company.

Other Events. On October 29, 2025, the Company issued a press release announcing that the Board authorized a common stock repurchase program (the “Stock Repurchase Program”) under which the Company may purchase up to $25 million of its common stock as market conditions warrant. The Repurchase Program will allow the Company to repurchase shares opportunistically at prices that the Company deems appropriate and subject to market conditions, applicable law and other factors deemed relevant in th…

Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 6,022,869 shares of the Company’s Common Stock, par value $0.00000002 per share (the “Common Stock”), at an offering price of $3.4199 per Pre-Funded Warrant. The Pre-Funded Warrants were immediately exercisable, and were issued to one of the investors under the securities purchase agreeme…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in

Entry into a Material Definitive Agreement. On September 3, 2025, MEI Pharma, Inc. (the “Company”), entered into a master loan agreement (the “Agreement”) with BitGo Prime, LLC (“Lender”). The Agreement creates a framework under which the Company may borrow any digital assets or cash from Lender from time to time. Each loan is documented in a separate loan request agreed to by the parties setting forth the specific terms, including principal amount, fees, collateral requirements, and the date…

Director — Steven D. Wood: Steven D. Wood resigned as a director, and Joshua Riezman was elected to the Board.

Other Events. The Company announced that during the period beginning July 30, 2025 through August 4, 2025, the Company acquired 929,548 Litecoin (LTC) tokens at an average price of $107.58, utilizing all of the net proceeds under the PIPE Offering with Titan Partners Group LLC, a division of American Capital Partners, LLC, as placement agent.

Regulation FD Disclosure. On August 5, 2025, MEI Pharma, Inc. (the “Company”) issued a press release announcing the Company’s acquisitions to date of Litecoin (LTC) tokens, reflecting the deployment of all of the net proceeds of the Company’s previously announced sales of common stock and pre-funded warrants under the securities purchase agreements entered into on July 17, 2025 by the Company and the various purchasers thereunder in a private placement offering (the “PIPE Offering”). The Comp…

Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, the Company issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 6,022,869 shares of the Company’s Common Stock, par value $0.00000002 per share (the “Common Stock”), at an offering price of $3.4199 per Pre-Funded Warrant. The Pre-Funded Warrants were immediately exercisable, and were issued to one of the investors under the securities purchase agreements entered into on July…

Termination of a Material Definitive Agreement. Effective July 22, 2025, upon closing of the Offering, the parties to the Cooperation Agreement (as defined in

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.

Entry into a Material Definitive Agreement. Securities Purchase Agreements On July 17, 2025, MEI Pharma, Inc. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with certain investors (the “Purchasers”) pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement offering (the “Offering”) an aggregate of (i) 23,216,898 shares (the “Shares”) of common stock of the Company, par value $0. 00000002 per share (the “…

Other Events. On July 22, 2025 , the Company entered into a Sales Agreement (the “Sales Agreement”) with Titan (in such capacity, the “Agent”), pursuant to which the Company may sell, from time to time, at its option, up to $100,000,000 in aggregate principal amount of an indeterminate amount of shares (the “ATM Shares”) of Common Stock, through the Agent, as the Company’s sales agent. Any ATM Shares to be offered and sold under the Sales Agreement will be issued and sold (i) by methods deeme…

Director — Taheer Datoo: Taheer Datoo tendered his resignation from the Board due to Investors no longer owning the Minimum Ownership Amount.

Results of Operations and Financial Condition. On May 13, 2025, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2025. The text of the press release is included as an exhibit to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…

Justin J. File: Amendment and restatement of employment agreement with no change in role or departure.

Results of Operations and Financial Condition. On February 12, 2025, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended December 31, 2024. The text of the press release is included as an exhibit to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…